'This lawsuit is a desperate attempt by the industry to beat back popular legislation that would curtail Big Pharma's ability to price gouge Medicare,' said Rob_Weissman of Public_Citizen.
in a statement Tuesday."This lawsuit is a desperate attempt by the industry to beat back popular legislation that would curtail Big Pharma's ability to price gouge Medicare and secure monopoly profits. Full stop."
"While Big Pharma's litigation gambit plays out, it is critical that the federal government continue its preparation for price negotiations," Weissman added."Delay in the commencement of long-overdue negotiations will result in billions of dollars in excess costs for taxpayers and consumers." "No one needs to read Merck's fancy lawyer talk or PR spin to know what this is all about—it is about them wanting to continue to fleece taxpayers and gouging seniors."a list of the first 10 Medicare Part D drugs that will be subject to direct price negotiations. Manufacturers of the selected drugs will then have until the following month to sign an agreement to conduct negotiations, and the agreed-upon prices will take effect in 2026.
"Merck had been expecting to bring in significant revenue from a new formulation of Keytruda it is developing that can be more easily given under the skin," thereported."That could be subject to negotiation, too, under the government's plans for the program.
"No one needs to read Merck's fancy lawyer talk or PR spin to know what this is all about—it is about them wanting to continue to fleece taxpayers and gouging seniors so they can keep sky-high profits and soaring executive pay," said Jorge."It's time for big drug corporations like Merck to give up their monopoly control over prices and negotiate fair prices for the medicines we need.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.Big pharma will be looking to acquire companies with promsing new medicines.
Leer más »
Medicare Trustees Report for 2023 contained no bad newsExpenditures remain high -- primarily due to high healthcare costs, not program generosity
Leer más »
Merck sues Biden administration over Medicare drug price negotiationsIn a scathing complaint filed in federal district court, Merck excoriated the Medicare price negotiation process as a 'sham' and 'tantamount to extortion.'
Leer más »
Merck sues HHS over drug negotiation, claims program ‘tantamount to extortion’In its suit, the drug giant claims that Medicare negotiation program is unconstitutional
Leer más »
Pharma company Purolite is investing $190 million in a Chester County facilityPurolite, the King of Prussia company that makes resin beads for water-purification and medical pills will convert the former W.L. Gore facility into a factory.
Leer más »
N.J. drugmaker sues federal government, calling plan to negotiate Medicare drug prices ‘extortion’The company is seeking to halt the program, which is expected to save taxpayers billions of dollars in the coming years.
Leer más »